Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Nymox Pharmaceutical Corporation is a biotechnology business based in the US. Nymox Pharmaceutical Corporation shares (NYMX) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$1.66 - USD$4.79 |
---|---|
50-day moving average | USD$2.7239 |
200-day moving average | USD$2.4398 |
Wall St. target price | USD$10.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.207 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$31,000 |
---|---|
Gross profit TTM | USD$58,000 |
Return on assets TTM | -117.52% |
Return on equity TTM | -261.18% |
Profit margin | 0% |
Book value | $0.05 |
Market capitalisation | USD$232.4 million |
TTM: trailing 12 months
There are currently 3.5 million Nymox Pharmaceutical Corporation shares held short by investors – that's known as Nymox Pharmaceutical Corporation's "short interest". This figure is 4.5% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting Nymox Pharmaceutical Corporation shares can be evaluated.
Nymox Pharmaceutical Corporation's "short interest ratio" (SIR) is the quantity of Nymox Pharmaceutical Corporation shares currently shorted divided by the average quantity of Nymox Pharmaceutical Corporation shares traded daily (recently around 132010.80773606). Nymox Pharmaceutical Corporation's SIR currently stands at 26.37. In other words for every 100,000 Nymox Pharmaceutical Corporation shares traded daily on the market, roughly 26370 shares are currently held short.
However Nymox Pharmaceutical Corporation's short interest can also be evaluated against the total number of Nymox Pharmaceutical Corporation shares, or, against the total number of tradable Nymox Pharmaceutical Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nymox Pharmaceutical Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Nymox Pharmaceutical Corporation shares in existence, roughly 50 shares are currently held short) or 0.078% of the tradable shares (for every 100,000 tradable Nymox Pharmaceutical Corporation shares, roughly 78 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Nymox Pharmaceutical Corporation.
Find out more about how you can short Nymox Pharmaceutical Corporation stock.
We're not expecting Nymox Pharmaceutical Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Nymox Pharmaceutical Corporation's shares have ranged in value from as little as $1.66 up to $4.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nymox Pharmaceutical Corporation's is 1.4861. This would suggest that Nymox Pharmaceutical Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company operates in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.